Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back

Guillaume Marquis-Gravel, MD, MSc

Interventional Cardiologist, Assistant Professor
Montreal Heart Institute
Montreal Heart Institute

Dr. Guillaume Marquis-Gravel is an interventional cardiologist at the Montreal Heart Institute, and an assistant professor at Université de Montréal since 2020. He is a Junior 1 clinical research scholar of the Fonds de la Recherche du Québec – Santé (FRQS). He completed his medical training (M.D.), a Masters in Biomedical Sciences (M.Sc., with Honors), a residency in internal medicine, and a residency in adult cardiology (with Honors) at the Université de Montréal. He then completed a 1-year clinical fellowship in interventional cardiology at Duke University (Durham, NC, United States), followed by a 2-year clinical research fellowship at the Duke Clinical Research Institute. He is the primary author or co-author of more than 110 peer-reviewed publications, including in the New England Journal of Medicine, JAMA Cardiology, the Journal of the American College of Cardiology, and Circulation, and of 5 book chapters. He is an associate editor of the Canadian Journal of Cardiology. His main research interests revolve around the antithrombotic management of acute and chronic coronary artery disease, prevention of contrast-induced nephropathy after PCI, and development of innovative clinical trial methods. He is the principal investigator of research projects funded by the Canadian Institutes of Health Research (CIHR), the Heart & Stroke Foundation, and the Canadian Heart Function Alliance. He is the co-chair of the 2023 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.

Disclosure(s): Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, December 7, 2021), Speaker/Honoraria (Terminated, December 7, 2021); Boston Scientific: Consultant/Advisory Board (Terminated, May 12, 2022); CSI: Speaker/Honoraria (Terminated, April 26, 2022); HLS Therapeutics: Consultant/Advisory Board (Terminated, April 20, 2023); JAMP Pharma: Consultant/Advisory Board (Terminated, April 16, 2024), Speaker/Honoraria (Terminated, April 16, 2024); KYE: Consultant/Advisory Board (Terminated, May 11, 2022), Speaker/Honoraria (Terminated, May 11, 2022); Novartis: Consultant/Advisory Board (Terminated, September 18, 2023), Consultant/Advisory Board (Terminated, September 18, 2023), Speaker/Honoraria (Terminated, September 18, 2023); Pharmascience: Speaker/Honoraria (Terminated, April 14, 2022)

Presentation(s):